For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for  days for female and male patients, of the final FOLFIRI dose. Patients who receive single agent napabucasin without FOLFIRI must agree to use contraception or take measures to avoid pregnancy during the study and for  days for female patients and  days for male patients, of the final napabucasin dose.
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the DSP- Dosing Emulsion dose
Subject (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug.
Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for  days after the last dose of ARQ .
Subjects (male and female) of childbearing/reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug
Male or female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during and after the study (six months after the last dose of paclitaxel or  months after the last dose of ARQ  whichever is longer)
Subject (male and female) of childbearing/ reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug.
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last dose
Male or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI dose.
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last dose
Male or female patients of child-producing potential agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI dose.
Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug; male and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, or avoidance of intercourse during the study and for  months after last investigational drug dose received
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI dose
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI dose.
Men or women of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoid intercourse during the study and for  days after the last dose of study drug
Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for  days after the last dose of ARQ 
For male or female patient of child producing potential: Must agree to use contraception or take measures to avoid pregnancy during the study and for  months after the final dose of Paclitaxel or for  days for female patients and for  days for male patients, of the final BBI/Placebo dose if Paclitaxel was not administered.
Male subjects and WOCBP must agree to use double barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug
Subject (male and female) of childbearing/ reproductive potential must agree to use double barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug.
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI or BBI dose
Male and female patients reproductive potential must agree to use measures to avoid pregnancy throughout the study and for  months following discontinuing study drug.
Agree to use double-barrier contraceptive measures or avoid intercourse during the study and for  days after the last dose of study drug
Male and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for  days after last investigational drug dose received
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for  days after the last BBI dose
